Concepedia

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Tatiana Strava Corrêa, Gustavo Duarte Ramos Matos, M. Soriano Segura, Carlos Henrique dos Anjos

Case Reports in Oncology · 2018 · 31 citations · 13 references

DOIFull text

Open access

Abstract

We report the case of a patient with SDC treated with T-DM1, with a very good response. Salivary carcinoma is a rare disease for which no randomized clinical trials are available. The maintenance of HER2 blockage might be important in this disease.

References

13

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.7K citations · Full text

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Clinical and immunohistologic typing of salivary duct carcinoma

M Jaehne, Kerstin Roeser, Thorsten Jaekel et al. · Cancer · 2005 · 315 citations · Full text

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

Robert I. Haddad, A. Dimitrios Colevas, Jeffrey F. Krane et al. · Oral Oncology · 2003 · 262 citations

, , +6

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.

Michael F. Press, Malcolm C. Pike, Gene Hung et al. · PubMed · 1994 · 222 citations

, , +16